Spineology Pockets $25M in Equity Financing

Spineology has raised $25 million in Series AA financing led by led by SV Health Investors, with participation from 1315 Capital and its existing investor, RC Capital.
 
The company’s OptiMesh is touted as the only in-situ patient-specific, expandable implant on the market. It’s delivered through the smallest insertion portal of any lumbar interbody and dynamically conforms to a patient’s endplate morphology. It also expands to one of the largest implant footprints available, according to the company.
 
A single implant can be used for multiple lumbar fusion approaches. OptiMesh is supported by IDE level data and has the only de novo grant for spinal fusion. It’s designed to provide faster post-op healing and return to a high quality of life.
 
“We are thrilled to welcome SV Health Investors and 1315 Capital. This infusion of capital allows us to provide our offering more rapidly to patients and clinical programs across the country,” said Brian Snider, Spineology’s CEO. “OptiMesh’s powerful distraction forces and conformance to the endplates provide strength and stability to restore disc height, achieve alignment goals, and promote robust fusion. It is evident that surgeons and patients desire less disruptive options to treat spinal disorders, further accelerating our opportunity.”
 
In April, the company announced that former Alphatec VP of sales Emory Rooney joined Spineology as its executive VP of sales.